Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
3.39
USD
+0.30%
-3.69%
+129.05%
Trovagene, Inc. Announces Resignation of Dr. Stanley Tennant as Director, Effective December 31, 2018
December 14, 2018 at 04:31 pm EST
On December 10, 2018, Dr. Stanley Tennant resigned as a director of Trovagene, Inc. for personal reasons, effective December 31, 2018.
Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 02
CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study
Apr. 08
CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating
Mar. 06
MT
Sector Update: Health Care Stocks Rising Late Afternoon
Mar. 01
MT
Sector Update: Health Care
Mar. 01
MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy
Mar. 01
MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating
Mar. 01
MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Feb. 29
CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC
Feb. 29
CI
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 29
CI
Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Nov. 02
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 02
CI
Top Premarket Gainers
23-09-27
MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields
23-09-27
DJ
Cardiff Oncology Reports 'Positive' Results From Onvansertib Monotherapy Trial for Pancreatic, Small Cell Lung Cancers
23-09-26
MT
Transcript : Cardiff Oncology, Inc. - Special Call
23-09-26
Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy
23-09-26
CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index
23-09-18
CI
North American Morning Briefing : Stock Futures -2-
23-08-16
DJ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating
23-08-11
MT
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Sector Update: Health Care Stocks Gaining Late Tuesday
23-08-08
MT
Sector Update: Health Care
23-08-08
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
More about the company
Last Close Price
3.39
USD
Average target price
9.833
USD
Spread / Average Target
+190.07%
Consensus
1st Jan change
Capi.
+129.05% 152M +17.96% 44.96B +1.17% 42.65B +48.77% 41.85B -4.27% 29.04B +11.42% 26.08B -21.39% 19.03B +4.86% 12.75B +27.29% 12.06B -3.50% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1